JP2022536122A5 - - Google Patents

Info

Publication number
JP2022536122A5
JP2022536122A5 JP2021572597A JP2021572597A JP2022536122A5 JP 2022536122 A5 JP2022536122 A5 JP 2022536122A5 JP 2021572597 A JP2021572597 A JP 2021572597A JP 2021572597 A JP2021572597 A JP 2021572597A JP 2022536122 A5 JP2022536122 A5 JP 2022536122A5
Authority
JP
Japan
Prior art keywords
seq
cells
tumor
protein
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021572597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536122A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036481 external-priority patent/WO2020247859A2/en
Publication of JP2022536122A publication Critical patent/JP2022536122A/ja
Publication of JP2022536122A5 publication Critical patent/JP2022536122A5/ja
Priority to JP2025120504A priority Critical patent/JP2025157424A/ja
Pending legal-status Critical Current

Links

JP2021572597A 2019-06-07 2020-06-05 腫瘍関連抗原特異的ｔ細胞応答 Pending JP2022536122A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025120504A JP2025157424A (ja) 2019-06-07 2025-07-17 腫瘍関連抗原特異的ｔ細胞応答

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962858756P 2019-06-07 2019-06-07
US62/858,756 2019-06-07
US201962878511P 2019-07-25 2019-07-25
US62/878,511 2019-07-25
PCT/US2020/036481 WO2020247859A2 (en) 2019-06-07 2020-06-05 Tumor-associated antigen-specific t cell responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025120504A Division JP2025157424A (ja) 2019-06-07 2025-07-17 腫瘍関連抗原特異的ｔ細胞応答

Publications (2)

Publication Number Publication Date
JP2022536122A JP2022536122A (ja) 2022-08-12
JP2022536122A5 true JP2022536122A5 (cg-RX-API-DMAC7.html) 2023-06-12

Family

ID=73653372

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021572597A Pending JP2022536122A (ja) 2019-06-07 2020-06-05 腫瘍関連抗原特異的ｔ細胞応答
JP2025120504A Pending JP2025157424A (ja) 2019-06-07 2025-07-17 腫瘍関連抗原特異的ｔ細胞応答

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025120504A Pending JP2025157424A (ja) 2019-06-07 2025-07-17 腫瘍関連抗原特異的ｔ細胞応答

Country Status (5)

Country Link
US (1) US20220257740A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980071A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022536122A (cg-RX-API-DMAC7.html)
CN (1) CN114206385A (cg-RX-API-DMAC7.html)
WO (1) WO2020247859A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023115459A1 (zh) * 2021-12-23 2023-06-29 青岛华赛伯曼医学细胞生物有限公司 一种肿瘤抗原/mhc-i复合物及其制备方法和用途
JP2025508970A (ja) * 2022-03-02 2025-04-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｈｌａ－ａ＊０２：０１制限ヒト前立腺酸性ホスファターゼ（ｐａｐ）エピトープとの反応性を示すヒトｔ細胞受容体対
GB202406990D0 (en) * 2024-05-16 2024-07-03 Univ Oxford Innovation Ltd T cell receptors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031542A1 (en) * 1998-11-24 2000-06-02 Thomas Jefferson University Detection of t cell stimulating tumor antigens
AU2008312444B2 (en) * 2007-10-18 2014-02-06 Bavarian Nordic A/S Use of MVA to treat prostate cancer
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
TR201802741T4 (tr) * 2010-05-14 2018-03-21 Univ Oregon Health & Science Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.
JP6816031B2 (ja) * 2015-02-10 2021-01-20 オレゴン ヘルス アンド サイエンス ユニバーシティ 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
CN108474003A (zh) * 2015-11-20 2018-08-31 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
CN109843321A (zh) * 2016-06-22 2019-06-04 国际艾滋病疫苗行动组织公司 作为结核病疫苗的重组巨细胞病毒载体
US10532099B2 (en) * 2016-10-18 2020-01-14 Oregon Health & Science University Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules

Similar Documents

Publication Publication Date Title
JP2021191265A5 (cg-RX-API-DMAC7.html)
RU2360923C2 (ru) Новый лиганд рецептора цитокина zcytor17
Gershon et al. Early transcription factor subunits are encoded by vaccinia virus late genes.
IL299249B1 (en) Genetically modified immune cells that include adapted shrna-microRNA (shrnamir)
JP2022536122A5 (cg-RX-API-DMAC7.html)
JP2019511236A5 (cg-RX-API-DMAC7.html)
JP2017018125A5 (cg-RX-API-DMAC7.html)
CN114262690A (zh) 减毒的痘苗病毒的克隆毒株及其使用方法
WO1992001049A3 (en) Cd53 cell surface antigen and use thereof
WO2001070174A8 (en) Vegf-modulated genes and methods employing them
CN103160530B (zh) 一种融合基因及其应用
JP2024116193A5 (cg-RX-API-DMAC7.html)
JP2013523084A5 (cg-RX-API-DMAC7.html)
JP2026063215A5 (cg-RX-API-DMAC7.html)
RU2012147590A (ru) Пептиды cdca5 и содержащие их вакцины
JP2022535458A5 (cg-RX-API-DMAC7.html)
JP2024503091A5 (cg-RX-API-DMAC7.html)
CN116970058B (zh) 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用
CN113249408A (zh) 一种靶向激活体液免疫和细胞免疫的核酸疫苗载体构建及应用
JP2023515806A5 (cg-RX-API-DMAC7.html)
CN102178950B (zh) 一种亚单位疫苗免疫佐剂及应用
JP2020127419A5 (cg-RX-API-DMAC7.html)
JP2024534189A5 (cg-RX-API-DMAC7.html)
CN108018267B (zh) 一种靶向表观基因调控抗乙型肝炎病毒分子HBx1C及其应用
Acosta-Rivero et al. Improvement of human interferon HUIFNα2 and HCV core protein expression levels in Escherichia coli but not of HUIFNα8 by using the tRNAAGA/AGG